Evidence map›Paper›PMID 33649538›Full record

ArticleOncogene2021

The RanBP2/RanGAP1-SUMO complex gates β-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis.

Elodie Blondel-Tepaz, Marie Leverve, Badr Sokrat, Justine S Paradis, Milena Kosic, Kusumika Saha, Cédric Auffray, Evelyne Lima-Fernandes, Alessia Zamborlini, Anne Poupon and 8 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. SUMOylation as a Therapeutic Target for Myocardial Infarction.Frontiers in cardiovascular medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Elodie Blondel-TepazInserm, U1016, Institut Cochin, Paris, France.
Marie LeverveInserm, U1016, Institut Cochin, Paris, France.
Badr SokratInstitute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, Canada.
Justine S ParadisDepartment of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, Canada.
Milena KosicLeslie Dan Faculty of Pharmacy and Department of Biochemistry, University of Toronto, Toronto, ON, Canada.
Kusumika SahaInserm, U1016, Institut Cochin, Paris, France.
Cédric AuffrayInserm, U1016, Institut Cochin, Paris, France.
Evelyne Lima-FernandesInserm, U1016, Institut Cochin, Paris, France.ORCID http://orcid.org/0000-0002-3628-9745
Alessia ZamborliniInstitute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Université Paris-Saclay, Gif-sur-Yvette, France.
Anne PouponPRC, INRA, CNRS, IFCE, Université de Tours, Nouzilly, France.
Louis GabouryDepartment of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, Canada.
Jane FindlayInstitute of Cardiovascular and Medical Sciences, College of Veterinary, Medical and Life Sciences, University of Glasgow, Glasgow, UK.
George S BaillieInstitute of Cardiovascular and Medical Sciences, College of Veterinary, Medical and Life Sciences, University of Glasgow, Glasgow, UK.
Hervé EnslenInserm, U1016, Institut Cochin, Paris, France.ORCID http://orcid.org/0000-0001-9741-5293
Michel BouvierDepartment of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, Canada.ORCID http://orcid.org/0000-0003-1128-0100
Stéphane AngersLeslie Dan Faculty of Pharmacy and Department of Biochemistry, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-7241-9044
Stefano MarulloInserm, U1016, Institut Cochin, Paris, France.ORCID http://orcid.org/0000-0001-9604-9973
Mark G H ScottInserm, U1016, Institut Cochin, Paris, France. mark.scott@inserm.fr.ORCID http://orcid.org/0000-0002-1557-1856
Centre National de la Recherche Scientifique · FRInstitute for Research in Immunology and Cancer · CAUniversité de Montréal · CAUniversity of Glasgow · GBUniversity of Toronto · CAUniversité de Tours · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mdm2 antagonizes the tumor suppressor p53. Targeting the Mdm2-p53 interaction represents an attractive approach for the treatment of cancers with functional p53. Investigating mechanisms underlying Mdm2-p53 regulation is therefore important. The scaffold protein β-arrestin2 (β-arr2) regulates tumor suppressor p53 by counteracting Mdm2. β-arr2 nucleocytoplasmic shuttling displaces Mdm2 from the nucleus to the cytoplasm resulting in enhanced p53 signaling. β-arr2 is constitutively exported from the nucleus, via a nuclear export signal, but mechanisms regulating its nuclear entry are not completely elucidated. β-arr2 can be SUMOylated, but no information is available on how SUMO may regulate β-arr2 nucleocytoplasmic shuttling. While we found β-arr2 SUMOylation to be dispensable for nuclear import, we identified a non-covalent interaction between SUMO and β-arr2, via a SUMO interaction motif (SIM), that is required for β-arr2 cytonuclear trafficking. This SIM promotes association of β-arr2 with the multimolecular RanBP2/RanGAP1-SUMO nucleocytoplasmic transport hub that resides on the cytoplasmic filaments of the nuclear pore complex. Depletion of RanBP2/RanGAP1-SUMO levels result in defective β-arr2 nuclear entry. Mutation of the SIM inhibits β-arr2 nuclear import, its ability to delocalize Mdm2 from the nucleus to the cytoplasm and enhanced p53 signaling in lung and breast tumor cell lines. Thus, a β-arr2 SIM nuclear entry checkpoint, coupled with active β-arr2 nuclear export, regulates its cytonuclear trafficking function to control the Mdm2-p53 signaling axis.

Indexed as

beta-Arrestin 2Cell Line, TumorCell NucleusCytoskeletonGTPase-Activating ProteinsHumansMutationNeoplasmsNuclear Export SignalsProto-Oncogene Proteins c-mdm2Signal TransductionSUMO-1 ProteinSumoylationTumor Suppressor Protein p53ARRB2 protein, humanbeta-Arrestin 2GTPase-Activating ProteinsMDM2 protein, humanNuclear Export SignalsProto-Oncogene Proteins c-mdm2RANGAP1 protein, humanSUMO-1 ProteinTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID33649538
OpenAlexW3135392879

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.